Amgen Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 06/03/2023

Stock Rating
7
Price Target
$278.00
Consensus
Neutral
Upside
27.48%
Analysts
11
Stock Rating
7
Upside
27.48%
Analysts
11
Price Target
$278.00

Amgen Inc Stock Forecast and Price Target

Amgen Inc's most recent price target of $278.00 for 2023 was provided by eleven renowned analysts over the past few months, with an average prediction of $278.00. If this prediction is correct, Amgen Inc's stock could rise by 27.48 percent from its current trading price. The potential increase for the stock is $278.00 per share, with a possible range of $180.00 to $325.00. If you are interested in AMGN stock, you should also look at its competitors.

$278.00

27.48% Upside

Hold
Hold

Amgen Inc Fair Value Forecast for 2023 - 2025 - 2030

Amgen Inc's Price has increased by 15.38% In the last two years, going from $201.70 to $232.73. In the next year, analysts expect Fair Value to reach $261.99 – an increase of 12.57%. For the next eight years, the forecast is for Fair Value to grow by 41.11%.

2023 Fair Value Forecast
$261.99
2024 Fair Value Forecast
$288.26
2025 Fair Value Forecast
$295.88
2026 Fair Value Forecast
$307.72
2027 Fair Value Forecast
$320.24
2028 Fair Value Forecast
$321.20
2029 Fair Value Forecast
$310.17
2030 Fair Value Forecast
$328.41
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 10
$136.87 Buy/Sell $162.24 20.55%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$77.89 Buy/Sell $87.30 12.98%
BIIB Stock Forecast Biogen Inc Outperform 11
$300.20 Buy/Sell $322.44 8.26%
NasdaqGS:ALXN Stock Forecast Alexion Pharmaceuticals - 15
$182.50 Buy/Sell $177.38 29.40%
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$93.36 Buy/Sell $115.45 28.53%

Amgen Inc Revenue Forecast for 2023 - 2025 - 2030

Amgen Inc's Revenue has increased by 12.67% In the last three years, going from $23.36B to $26.32B. In the next year, analysts expect Revenue to reach $27.32B – an increase of 3.78%. For the next eight years, the forecast is for Revenue to grow by 6.58%.

2023 Rev Forecast
$27.32B
2024 Rev Forecast
$28.62B
2025 Rev Forecast
$28.96B
2026 Rev Forecast
$29.35B
2027 Rev Forecast
$29.95B
2028 Rev Forecast
$29.64B
2029 Rev Forecast
$28.43B
2030 Rev Forecast
$28.05B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INCY Stock Forecast Incyte Outperform 9
$62.54 Buy/Sell $88.18 37.51%
ARNA Stock Forecast Arena Pharmaceuticals - 6
$99.99 Buy/Sell $95.80 11.05%
EXEL Stock Forecast Exelixis Outperform 16
$19.19 Buy/Sell $24.94 30.28%

Amgen Inc Dividend per Share Forecast for 2023 - 2025 - 2030

In the last three years, Amgen Inc's Dividend per Share has grown, increasing from $5.80 to $8.52 – a growth of 46.90%. In the following year, 11 experts forecast Amgen Inc's Dividend per Share will decrease by 2.82%, to $8.28. Over the next eight years, experts anticipate that Amgen Inc's Dividend per Share will grow at a rate of 48.36%.

2023 DPS Forecast
$8.28
2024 DPS Forecast
$9.30
2025 DPS Forecast
$9.81
2026 DPS Forecast
$10.70
2027 DPS Forecast
$11.14
2028 DPS Forecast
$11.14
2029 DPS Forecast
$11.87
2030 DPS Forecast
$12.64
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ARWR Stock Forecast Arrowhead Pharmaceuticals Outperform 7
$36.05 Buy/Sell $73.38 108.04%
CCXI Stock Forecast ChemoCentryx Outperform 8
$51.99 Buy/Sell $34.75 24.06%
DRNA Stock Forecast Dicerna Pharmaceuticals - 7
$38.22 Buy/Sell $39.67 10.83%

Amgen Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Amgen Inc's Free Cash Flow has grown from $8.53B to $8681.00T – a 101746259.49% increase. In the next year, 5 analysts estimate that Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $10.40B. According to professional forecasts, in 2030, Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $12.27B.

2023 FCF Forecast
$10.40B
2024 FCF Forecast
$11.22B
2025 FCF Forecast
$11.38B
2026 FCF Forecast
$11.92B
2027 FCF Forecast
$12.85B
2028 FCF Forecast
$12.95B
2029 FCF Forecast
$12.66B
2030 FCF Forecast
$12.27B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
FOLD Stock Forecast Amicus Therapeutics Outperform 7
$12.17 Buy/Sell $14.60 23.25%
BCRX Stock Forecast BioCryst Pharmaceuticals Outperform 7
$8.35 Buy/Sell $17.08 55.69%
ACAD Stock Forecast ACADIA Pharmaceuticals Outperform 6
$24.61 Buy/Sell $29.50 -18.73%

Amgen Inc Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Amgen Inc's Net Income has seen a drop from $7.84B to $6.55B – a 16.45% decrease. For the next year, analysts are expecting Net Income to reach $10.25B – an increase of 56.44%. Over the next eight years, experts predict that Net Income will grow by 50.36%.

2023 NI Forecast
$10.25B
2024 NI Forecast
$11.03B
2025 NI Forecast
$11.12B
2026 NI Forecast
$11.35B
2027 NI Forecast
$11.12B
2028 NI Forecast
$10.76B
2029 NI Forecast
$10.04B
2030 NI Forecast
$9.85B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BPMC Stock Forecast Blueprint Medicines Outperform 6
$44.99 Buy/Sell $119.23 74.48%
SAGE Stock Forecast Sage Therapeutics Outperform 6
$49.82 Buy/Sell $101.45 8.39%
IOVA Stock Forecast Iovance Biotherapeutics Outperform 4
$8.80 Buy/Sell $34.92 206.82%

Amgen Inc EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Amgen Inc's EBITDA has fallen from $11.76B to $8.75B – a 25.55% decrease. For next year, analysts predict EBITDA of $16.28B, which would mean an increase of 85.98%. Over the next eight years, experts predict that Amgen Inc's EBITDA will grow at a rate of 49.55%.

2023 EBITDA Forecast
$16.28B
2024 EBITDA Forecast
$16.97B
2025 EBITDA Forecast
$16.21B
2026 EBITDA Forecast
$15.23B
2027 EBITDA Forecast
$15.12B
2028 EBITDA Forecast
$15.25B
2029 EBITDA Forecast
$14.39B
2030 EBITDA Forecast
$13.09B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
FATE Stock Forecast Fate Therapeutics Outperform 7
$5.25 Buy/Sell $109.67 1461.90%
DVAX Stock Forecast Dynavax Technologies Buy 11
$11.66 Buy/Sell $22.67 127.27%
XNCR Stock Forecast Xencor Buy 6
$27.69 Buy/Sell $55.00 78.76%

Amgen Inc EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Amgen Inc's EBIT has decreased from $9.72B to $9.34B – a 3.94% drop. For next year, analysts predict EBIT of $13.01B, which would mean an increase of 39.31%. Over the next eight years, experts predict that Amgen Inc's EBIT will grow at a rate of 35.96%.

2023 EBIT Forecast
$13.01B
2024 EBIT Forecast
$13.71B
2025 EBIT Forecast
$13.77B
2026 EBIT Forecast
$13.75B
2027 EBIT Forecast
$13.89B
2028 EBIT Forecast
$13.59B
2029 EBIT Forecast
$12.89B
2030 EBIT Forecast
$12.70B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CLDX Stock Forecast Celldex Therapeutics Buy 11
$33.19 Buy/Sell $64.83 104.88%
TVTX Stock Forecast Travere Therapeutics Buy 8
$19.05 Buy/Sell $41.00 120.47%
AGIO Stock Forecast Agios Pharmaceuticals Outperform 9
$26.05 Buy/Sell $53.75 49.71%

Amgen Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

Amgen Inc's EPS has increased by 15.38% In the last two years, going from $14.82 to $17.10. In the next year, analysts expect EPS to reach $19.25 – an increase of 12.57%. For the next eight years, the forecast is for EPS to grow by 41.11%.

2023 EPS Forecast
$19.25
2024 EPS Forecast
$21.18
2025 EPS Forecast
$21.74
2026 EPS Forecast
$22.61
2027 EPS Forecast
$23.53
2028 EPS Forecast
$23.60
2029 EPS Forecast
$22.79
2030 EPS Forecast
$24.13
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ENTA Stock Forecast Enanta Pharmaceuticals Outperform 10
$25.93 Buy/Sell $90.20 158.39%
VCEL Stock Forecast Vericel Buy 8
$32.93 Buy/Sell $44.60 51.84%
RVNC Stock Forecast Revance Therapeutics Outperform 6
$31.06 Buy/Sell $38.55 -17.90%